Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2023 | Gemcitabine, cisplatin, and nab-paclitaxel in advanced biliary tract cancers

Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, discusses data from the Phase III SWOG 1815 trial (NCT03768414) of gemcitabine, cisplatin, and nab-paclitaxel in newly diagnosed, advanced biliary tract cancers. The investigational treatment regimen failed to significantly improve outcomes compared to the standard of care, whereas patients with gallbladder cancer and locally advanced disease may receive some benefit. Gemcitabine, cisplatin, and durvalumab remains the superior treatment combination, following findings from the TOPAZ-1 trial (NCT03875235). This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.